Device Catheter Care and Medication Delivery

Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire

Payments companies reported to CMS as associated with Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$5,457associated payments (2023-2025)
93clinicians with associated payments
4companies reporting

By year

2023 $1,434
2024 $2,829
2025 $1,194

Payments reported as associated with Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $3,196
Pediatric Urology $1,122
Family $274
Physician Assistant $211
Vascular Surgery $201
Surgical $191

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire

These are the largest totals companies reported as associated with Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Daniel Nassau Miami, FL Pediatric Urology $334.51
Jamil Syed Vero Beach, FL Urology $202.25
David Yee Roseville, CA Urology $183.19
Osama Alalao Stuart, FL Urology $180.34
Andrew Labbie Miami, FL Pediatric Urology $174.53
Daniel Tennenbaum Miami, FL Urology $174.53
Miguel Castellan Miami, FL Pediatric Urology $174.53
Kevin Olson-Jason Atlanta, GA Surgical $174.52
Megan Daniel Jupiter, FL Family $174.52
Rafael Gosalbez Miami, FL Pediatric Urology $145.98

Prescribed Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.